{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-140688","form_type":"8-K","ticker":"RNTX","cik":"0001420565","company_name":"Rein Therapeutics, Inc.","filed_at":"2024-05-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.341587+00:00","generated_at":"2026-06-01T19:50:32.599773+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Aileron Therapeutics appoints Timothy Cunningham as interim CFO after Charles Garner departure","bullets":["Charles Garner departed as CFO on May 15, 2024; Timothy Cunningham appointed interim CFO effective May 16, 2024.","Cunningham is a consultant from Danforth Advisors, providing CFO services at an hourly rate under consulting agreement.","Cunningham, age 62, CPA, has served as CFO for Bionomics Limited and other biotech firms; no family relationships with executives."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-140688","json":"https://secwatch.observer/filing/0001193125-24-140688.json","markdown":"https://secwatch.observer/filing/0001193125-24-140688.md","text":"https://secwatch.observer/filing/0001193125-24-140688.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1420565/000119312524140688/0001193125-24-140688-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1420565/000119312524140688/d841479d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T19:50:32.599773+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5e4383b4ea","claim":"Timothy M. Cunningham was appointed as Interim Chief Financial Officer at Rein Therapeutics, Inc..","evidence_excerpt":"the Board of Directors of Aileron Therapeutics, Inc. (the “Company”) appointed Timothy M. Cunningham, a consultant at Danforth Advisors, LLC (“Danforth”), as interim chief financial officer, effective as of May 16, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1420565/000119312524140688/0001193125-24-140688-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Interim Chief Financial Officer"}]},{"claim_id":"82bd67ca6e","claim":"Charles Garner departed as Chief Financial Officer at Rein Therapeutics, Inc..","evidence_excerpt":"Mr. Garner's departure from the Company on May 15, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1420565/000119312524140688/0001193125-24-140688-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"departed"},{"label":"Role","value":"Chief Financial Officer"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}